A pivotal decade for bispecific antibodies?
Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of mAbs and their adoption as therapeutic agents in the 1980s and 1990s, the development of bsAbs has held substantial appeal...
Saved in:
Main Authors: | Marlena Surowka, Christian Klein |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2024.2321635 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01) -
Filozofia systemu zarządzania środowiskiem wg PN-EN ISO 14001: 1998
by: Jacek W. Czartoszewski
Published: (2004-12-01) -
Incidence of Apoptosis in the Lymphoid Organs of Normalor Malaria Infected Mice is Decreased in CD18 andUrokinase - Receptor (UPAR, CD87) Deficient Mice
by: Pierre Francois Piguet, et al.
Published: (2001-01-01) -
B.S. Johnson ou l’équilibre de l’écart
by: Vanessa Guignery
Published: (2011-12-01) -
Improving CD3 bispecific antibody therapy in solid tumors using combination strategies
by: Katy Lloyd, et al.
Published: (2025-02-01)